VEGFR-3抑制剂1 T72924
面议
- TargetMol
- 生产商
- 进口
- 美国
- 现货
- 全国
- 7
- 1
Product IntroductionBioactivity英文名: VEGFR-3-IN-1描述: VEGFR-3-IN-1 是一种新型有效且具有选择性的 VEGFR3 抑制剂，其 IC50 为 110.4 nM。VEGFR-3-IN-1
AI问答
配套的仪器设备？
可以搭配的相关耗材试剂？
耗材描述
Product Introduction
Bioactivity
英文名: VEGFR-3-IN-1
描述: VEGFR-3-IN-1 是一种新型有效且具有选择性的 VEGFR3 抑制剂，其 IC50 为 110.4 nM。VEGFR-3-IN-1 具有抗肿瘤活性，可使 VEGFR3 信号通路失活，可抑制 VEGF-C 诱导人真皮淋巴管内皮细胞 (HDLEC)、MDA-MB-231 和 MDA-MB-436 细胞的增殖和迁移，并且能有效抑制乳腺癌的生长。
体外活性: VEGFR-3-IN-1（100 nM；48小时）对MDA-MB-231和MDA-MB-436细胞展示出显著增强的抗增殖效能，其IC50值分别为2.22和3.50μM。[1] VEGFR-3-IN-1显著以剂量依赖的方式抑制VEGFR3及其下游蛋白的磷酸化。[1]
体内活性: VEGFR-3-IN-1 (50, 25 mg/kg; p.o.; once; Nude mice), with a growth inhibition rate of 61.9%, achieves the most potent inhibition of tumor volume in mice.[1]VEGFR-3-IN-1 (10 mg/kg; p.o.) treatment results in the following values: Cmax of 420 ng/mL, AUC0-t of 9219 ng h/mL, AUC0-∞ of 12304 ng h/mL, and t1/2 of 16 hours.[1]
存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
溶解度: DMSO : 5 mg/mL (8.12 mM)
相关产品: SU5204 | Cediranib | ZM 306416 | SU 4981 | Parsatuzumab | CP-547632 | CP-673451 | Cabozantinib | Bevacizumab | BGB-102
相关库: Anti-Cancer Compound Library | Membrane Protein-targeted Compound Library | Bioactive Compounds Library Max | Kinase Inhibitor Library | Inhibitor Library | Tyrosine Kinase Inhibitor Library | Anti-Cancer Active Compound Library | Bioactive Compound Library
Bioactivity
英文名: VEGFR-3-IN-1
描述: VEGFR-3-IN-1 是一种新型有效且具有选择性的 VEGFR3 抑制剂，其 IC50 为 110.4 nM。VEGFR-3-IN-1 具有抗肿瘤活性，可使 VEGFR3 信号通路失活，可抑制 VEGF-C 诱导人真皮淋巴管内皮细胞 (HDLEC)、MDA-MB-231 和 MDA-MB-436 细胞的增殖和迁移，并且能有效抑制乳腺癌的生长。
体外活性: VEGFR-3-IN-1（100 nM；48小时）对MDA-MB-231和MDA-MB-436细胞展示出显著增强的抗增殖效能，其IC50值分别为2.22和3.50μM。[1] VEGFR-3-IN-1显著以剂量依赖的方式抑制VEGFR3及其下游蛋白的磷酸化。[1]
体内活性: VEGFR-3-IN-1 (50, 25 mg/kg; p.o.; once; Nude mice), with a growth inhibition rate of 61.9%, achieves the most potent inhibition of tumor volume in mice.[1]VEGFR-3-IN-1 (10 mg/kg; p.o.) treatment results in the following values: Cmax of 420 ng/mL, AUC0-t of 9219 ng h/mL, AUC0-∞ of 12304 ng h/mL, and t1/2 of 16 hours.[1]
存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
溶解度: DMSO : 5 mg/mL (8.12 mM)
相关产品: SU5204 | Cediranib | ZM 306416 | SU 4981 | Parsatuzumab | CP-547632 | CP-673451 | Cabozantinib | Bevacizumab | BGB-102
相关库: Anti-Cancer Compound Library | Membrane Protein-targeted Compound Library | Bioactive Compounds Library Max | Kinase Inhibitor Library | Inhibitor Library | Tyrosine Kinase Inhibitor Library | Anti-Cancer Active Compound Library | Bioactive Compound Library
猜你喜欢
感兴趣产品